| Insideraktier | 666.731 shares |
| Total Insiders | 22 |
Insider-stemningsscore
Insider Sentiment Score viser, at virksomhederne bliver købt af virksomheders insidere.
Det er resultatet af en sofistikeret, multi-faktor kvantitativ model, der identificerer virksomheder med de højeste niveauer af insider-akkumulering. Scoringsmodellen bruger en kombination af nettoantallet af insidere, der har købt de foregående 90 dage, det samlede antal aktier købt som en procentdel af float og det samlede antal aktier ejet af insidere. Tallet går fra 0 til 100, hvor højere tal indikerer et højere niveau af akkumulering for sine jævnaldrende, og 50 er gennemsnittet.
Opdateringsfrekvens: Dagligt
Se Insiders Top Picks, som giver en liste over virksomheder med den højeste insider-akkumulering.
Officers sentiment score
Officer Sentiment Score finder virksomheder, der bliver købt af Corporate Officers.
Per definition er Corporate Officers Corporate Insiders, men i modsætning til nogle af de andre Insiders (10 % aktionærer og bestyrelsesmedlemmer), arbejder officerer for virksomheden på daglig basis, og de bruger deres egne penge, når de handler . (10 % aktionærer og bestyrelsesmedlemmer er ofte fondsforvaltere, der administrerer andres penge.) Som sådan er insiderhandler foretaget af embedsmænd meget mere betydningsfulde og bør behandles passende.
Ligesom Insider Sentiment Score er Officer Sentiment Score resultatet af en sofistikeret, multi-faktor kvantitativ model, der identificerer virksomheder med de højeste niveauer af officerakkumulering.
Opdateringsfrekvens: Dagligt
Se Insiders Top Picks, som giver en liste over virksomheder med højeste insider-stemning.
Nøgle Insider Metrics
Dette kort viser, hvordan virksomheden rangerer langs forskellige insider-metrics. Percentilrangen viser, hvordan denne virksomhed sammenligner sig med andre virksomheder på de amerikanske markeder. Højere placeringer er tegn på bedre situationer.
For eksempel er det generelt accepteret, at insider-køb er en positiv indikator, så virksomheder med flere insider-køb vil rangere højere end virksomheder med mindre insider-køb (eller endda insider-salg).
Procent af float købt af insidere (rangering)
Procent af float købt af insidere er det samlede antal aktier købt af insidere minus det samlede antal aktier solgt af insidere inden for de sidste 90 dage, divideret med den samlede float og ganget med 100.
Insiderhandelsdiagram
Sensei Biotherapeutics, Inc. insiderhandler er vist i følgende diagram. Insidere er embedsmænd, direktører eller betydelige investorer i en virksomhed. Generelt er det generelt ulovligt for insidere at foretage handler i deres virksomheder baseret på væsentlige, ikke-offentlige oplysninger. Dette betyder ikke, at det er ulovligt for dem at handle i deres egne virksomheder. De skal dog rapportere alle handler til SEC via en formular 4.
Insiderliste og lønsomhedsmålinger
Denne tabel viser listen over kendte insidere og genereres automatisk fra arkiveringer, der er videregivet til SEC. Ud over navnene, den seneste titel og direktør, officer eller 10 % ejerbetegnelse giver vi de seneste offentliggjorte besiddelser. Derudover giver vi, når det er muligt, den historiske handelspræstation for insideren. Den historiske handelspræstation er et vægtet gennemsnit af præstationen af faktiske købstransaktioner på det åbne marked foretaget af insideren. For mere information om, hvordan dette beregnes, se dette YouTube-webinar.
See our leaderboard of most profitable insider traders.
| Insider | Gennemsnitlig fortjeneste (%) | Aktier Ejet |
Dele Justeret |
|---|---|---|---|
|
Apeiron Investment Group Ltd.
10% Owner -
|
0 | 0 | |
| Samuel Broder Director - [D] | 8.932 | 447 | |
|
Cambrian BioPharma Inc
10% Owner -
|
130.142 | 130.142 | |
| John Celebi PRESIDENT AND CEO, Director - [D] [O] | 105.862 | 5.293 | |
| Erin Colgan CHIEF FINANCIAL OFFICER - [O] | 67.462 | 3.373 | |
| Jessie English Director - [D] | 8.932 | 447 | |
| Patrick Stephen Gallagher Chief Business Officer - [O] | 34.130 | 1.706 |
| Insider | Gennemsnitlig fortjeneste (%) | Aktier Ejet |
Dele Justeret |
|---|---|---|---|
| Christopher Gerry President & PEO - [O] | 1.574 | 1.574 | |
|
H&s Investments I Lp
10% Owner -
|
4.425.998 | 221.300 | |
|
H&s Ventures Llc
10% Owner -
|
4.425.998 | 221.300 | |
| Bob Holmen Director - [D] | 25.598 | 1.280 | |
| Kristian Humer Director - [D] | 8.932 | 447 | |
|
Millennium Management Llc
10% Owner -
|
147.731 | 147.731 | |
|
James Peyer
10% Owner -
|
130.142 | 130.142 |
| Insider | Gennemsnitlig fortjeneste (%) | Aktier Ejet |
Dele Justeret |
|---|---|---|---|
| Robert Hamilton Pierce Chief R&D Officer - [O] | 21.000 | 1.050 | |
| Thomas G Ricks Director - [D] | 343.863 | 17.193 | |
| William R Ringo Director - [D] | 23.399 | 1.170 | |
|
Henry Samueli
10% Owner -
|
4.425.998 | 221.300 | |
|
Susan Samueli
10% Owner -
|
4.425.998 | 221.300 | |
|
Michael Schulman
10% Owner -
|
4.425.998 | 221.300 | |
| Deneen Vojta Director - [D] | 8.932 | 447 | |
| der Horst Edward van CHIEF SCIENTIFIC OFFICER - [O] | 59.794 | 2.990 |
Report errors via our new Insider Auditing Tool
Track Records af insiderkøb - Kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i SNSE / Sensei Biotherapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Track Records af insidersalg - Kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i SNSE / Sensei Biotherapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Transaktionshistorik
Klik på linkikonet for at se den fulde transaktionshistorik. Transaktioner, der rapporteres som en del af en automatisk handelsplan 10b5-1, vil have et X i kolonnen markeret 10b-5.
| Fil Dato |
Handle Dato |
Form | Insider | Ticker | Sikkerhedstitel | Kode | Direkte | Dyrke motion Pris |
Enhed Pris |
Enheder Ændret |
Værdi Ændret (1K) |
Tilbage Muligheder |
Tilbage Aktier |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-01 | 2026-06-01 | 4 | Peyer James | SNSE | Common Stock | D | 21,1400 | -476 | -10 | 130.142 | ||||
| 2026-06-01 | 2026-06-01 | 4 | Peyer James | SNSE | Common Stock | D | 20,0000 | -24.524 | -490 | 130.618 | ||||
| 2026-06-01 | 2026-06-01 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 21,1400 | -476 | -10 | 130.142 | ||||
| 2026-06-01 | 2026-06-01 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 20,0000 | -24.524 | -490 | 130.618 | ||||
| 2026-05-15 | 2026-04-07 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 33,3800 | -1.108 | -37 | 133.986 | ||||
| 2026-05-15 | 2026-04-07 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 32,2467 | -300 | -10 | 133.986 | ||||
| 2026-05-15 | 2026-04-07 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 31,3843 | -4.423 | -139 | 133.986 | ||||
| 2026-05-15 | 2026-04-07 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 29,7146 | -205 | -6 | 133.986 | ||||
| 2026-05-15 | 2026-04-07 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 28,9417 | -2.115 | -61 | 133.986 | ||||
| 2026-05-15 | 2026-04-07 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 33,3800 | 1.108 | 37 | 133.986 | ||||
| 2026-05-15 | 2026-04-06 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 31,9628 | -45 | -1 | 141.029 | ||||
| 2026-05-15 | 2026-04-06 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 31,0227 | -1.214 | -38 | 141.029 | ||||
| 2026-05-15 | 2026-04-06 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 31,0200 | 1.104 | 34 | 141.029 | ||||
| 2026-05-15 | 2026-04-02 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 34,8007 | -1.134 | -39 | 144.974 | ||||
| 2026-05-15 | 2026-04-02 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 33,3470 | -374 | -12 | 144.974 | ||||
| 2026-05-15 | 2026-04-02 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 32,6041 | -1.794 | -58 | 144.974 | ||||
| 2026-05-15 | 2026-04-02 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 31,7510 | -1.265 | -40 | 144.974 | ||||
| 2026-05-15 | 2026-04-02 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 30,8638 | -3.099 | -96 | 144.974 | ||||
| 2026-05-15 | 2026-04-02 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 35,5472 | 701 | 25 | 144.974 | ||||
| 2026-05-15 | 2026-04-02 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 34,7524 | 1.276 | 44 | 144.974 | ||||
| 2026-05-15 | 2026-04-02 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 33,4704 | 26 | 1 | 144.974 | ||||
| 2026-05-15 | 3 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 127.095 | ||||||||
| 2026-05-15 | 2026-03-30 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 27,6800 | -370 | -10 | 145.678 | ||||
| 2026-05-15 | 2026-03-30 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 25,8501 | -518 | -13 | 145.678 | ||||
| 2026-05-15 | 2026-03-30 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 27,6800 | 370 | 10 | 145.678 | ||||
| 2026-05-15 | 2026-03-30 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 26,7000 | 1.176 | 31 | 145.678 | ||||
| 2026-05-15 | 2026-03-30 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 25,9900 | 4.995 | 130 | 145.678 | ||||
| 2026-05-15 | 2026-03-30 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 25,0784 | 2.992 | 75 | 145.678 | ||||
| 2026-05-15 | 2026-03-27 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 27,3690 | -36 | -1 | 142.360 | ||||
| 2026-05-15 | 2026-03-27 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 26,7652 | -469 | -13 | 142.360 | ||||
| 2026-05-15 | 2026-03-27 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 28,1301 | 294 | 8 | 142.360 | ||||
| 2026-05-15 | 2026-03-27 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 27,2826 | 4.384 | 120 | 142.360 | ||||
| 2026-05-15 | 2026-03-27 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 26,2933 | 10.643 | 280 | 142.360 | ||||
| 2026-05-15 | 2026-03-26 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 28,6882 | -1.274 | -37 | 131.370 | ||||
| 2026-05-15 | 2026-03-26 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 26,8797 | -583 | -16 | 131.370 | ||||
| 2026-05-15 | 2026-03-26 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 29,9788 | 1.025 | 31 | 131.370 | ||||
| 2026-05-15 | 2026-03-26 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 28,8539 | 2.601 | 75 | 131.370 | ||||
| 2026-05-15 | 2026-03-26 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 27,9467 | 1.327 | 37 | 131.370 | ||||
| 2026-05-15 | 2026-03-26 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 27,2267 | 778 | 21 | 131.370 | ||||
| 2026-05-15 | 2026-04-01 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 34,7464 | -46 | -2 | 147.731 | ||||
| 2026-05-15 | 2026-04-01 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 31,5200 | -1.104 | -35 | 147.731 | ||||
| 2026-05-15 | 2026-04-01 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 35,4554 | 3.401 | 121 | 147.731 | ||||
| 2026-05-15 | 2026-04-01 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 34,5863 | 1.613 | 56 | 147.731 | ||||
| 2026-05-15 | 2026-04-01 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 31,5309 | 1.161 | 37 | 147.731 | ||||
| 2026-05-15 | 2026-03-31 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 31,5200 | -87 | -3 | 146.657 | ||||
| 2026-05-15 | 2026-03-31 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 28,4050 | -5 | -0 | 146.657 | ||||
| 2026-05-15 | 2026-03-31 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 27,1147 | -57 | -2 | 146.657 | ||||
| 2026-05-15 | 2026-03-31 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 25,1676 | -1.251 | -31 | 146.657 | ||||
| 2026-05-15 | 2026-03-31 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 24,2843 | -191 | -5 | 146.657 | ||||
| 2026-05-15 | 2026-03-31 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 32,5962 | 411 | 13 | 146.657 | ||||
| 2026-05-15 | 2026-03-31 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 31,4512 | 1.957 | 62 | 146.657 | ||||
| 2026-05-15 | 2026-03-31 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 30,4754 | 186 | 6 | 146.657 | ||||
| 2026-05-15 | 2026-03-31 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 27,7838 | 17 | 0 | 146.657 | ||||
| 2026-05-15 | 2026-03-31 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 26,7259 | 1.048 | 28 | 146.657 | ||||
| 2026-05-15 | 2026-03-31 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 25,3209 | 1.770 | 45 | 146.657 | ||||
| 2026-05-15 | 2026-03-31 | 4 | MILLENNIUM MANAGEMENT LLC | SNSE | Common Stock | I | 24,6857 | 616 | 15 | 146.657 | ||||
| 2025-12-10 | 2025-12-09 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 7,9200 | -446 | -4 | 155.142 | ||||
| 2025-12-10 | 2025-12-09 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 8,0400 | -395 | -3 | 155.588 | ||||
| 2025-12-10 | 2025-12-09 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 6,4000 | 395 | 3 | 155.983 | ||||
| 2025-12-10 | 2025-12-09 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 7,9500 | -2.666 | -21 | 155.588 | ||||
| 2025-12-10 | 2025-12-09 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 8,5900 | -3.105 | -27 | 158.254 | ||||
| 2025-12-10 | 2025-12-09 | 4 | Peyer James | SNSE | Common Stock | I | 7,9200 | -446 | -4 | 155.142 | ||||
| 2025-12-10 | 2025-12-09 | 4 | Peyer James | SNSE | Common Stock | I | 8,0400 | -395 | -3 | 155.588 | ||||
| 2025-12-10 | 2025-12-09 | 4 | Peyer James | SNSE | Common Stock | I | 6,4000 | 395 | 3 | 155.983 | ||||
| 2025-12-10 | 2025-12-09 | 4 | Peyer James | SNSE | Common Stock | I | 7,9500 | -2.666 | -21 | 155.588 | ||||
| 2025-12-10 | 2025-12-08 | 4 | Peyer James | SNSE | Common Stock | I | 8,5900 | -3.105 | -27 | 158.254 | ||||
| 2025-12-08 | 2025-12-05 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 13,1600 | -42 | -1 | 161.359 | ||||
| 2025-12-08 | 2025-12-05 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 12,2900 | -1.745 | -21 | 161.401 | ||||
| 2025-12-08 | 2025-12-05 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 11,4000 | -14.508 | -165 | 163.146 | ||||
| 2025-12-08 | 2025-12-04 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 9,0600 | -5.000 | -45 | 177.654 | ||||
| 2025-12-08 | 2025-12-05 | 4 | Peyer James | SNSE | Common Stock | I | 13,1600 | -42 | -1 | 161.359 | ||||
| 2025-12-08 | 2025-12-05 | 4 | Peyer James | SNSE | Common Stock | I | 12,2900 | -1.745 | -21 | 161.401 | ||||
| 2025-12-08 | 2025-12-05 | 4 | Peyer James | SNSE | Common Stock | I | 11,4000 | -14.508 | -165 | 163.146 | ||||
| 2025-12-08 | 2025-12-04 | 4 | Peyer James | SNSE | Common Stock | I | 9,0600 | -5.000 | -45 | 177.654 | ||||
| 2025-11-24 | 3 | Gerry Christopher | SNSE | Common Stock | D | 1.574 | ||||||||
| 2025-02-26 | 2025-02-19 | 4 | Celebi John | SNSE | Common Stock | D | 0,4760 | -5.558 | -3 | 105.862 | ||||
| 2025-02-26 | 2025-02-19 | 4 | van der Horst Edward | SNSE | Common Stock | D | 0,4760 | -2.276 | -1 | 59.794 | ||||
| 2024-02-16 | 2024-02-15 | 4 | van der Horst Edward | SNSE | Common Stock | D | 0,7900 | -2.843 | -2 | 56.070 | ||||
| 2024-02-16 | 2024-02-15 | 4 | Celebi John | SNSE | Common Stock | D | 0,7900 | -5.891 | -5 | 105.420 | ||||
| 2024-02-16 | 2024-02-15 | 4 | Colgan Erin | SNSE | Common Stock | D | 0,7900 | -3.627 | -3 | 67.462 | ||||
| 2023-09-13 | 2023-09-11 | 4 | Celebi John | SNSE | Common Stock | D | 0,8500 | 500 | 0 | 111.311 | ||||
| 2023-09-11 | 2023-02-15 | 4 | Gallagher Patrick Stephen | SNSE | Common Stock | D | 1,5000 | -9.383 | -14 | 34.130 | ||||
| 2023-09-11 | 2023-02-15 | 4 | Celebi John | SNSE | Common Stock | D | 1,5000 | -20.492 | -31 | 110.811 | ||||
| 2023-09-11 | 2023-02-15 | 4 | van der Horst Edward | SNSE | Common Stock | D | 1,5000 | -9.525 | -14 | 52.913 | ||||
| 2023-09-11 | 2023-02-15 | 4 | Colgan Erin | SNSE | Common Stock | D | 1,5000 | -10.943 | -16 | 68.089 | ||||
| 2023-08-02 | 2023-07-31 | 4 | Peyer James | SNSE | Common Stock | I | 1,2600 | -1.587.302 | -2.000 | 3.653.120 | ||||
| 2023-08-02 | 2023-07-31 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 1,2600 | -1.587.302 | -2.000 | 3.653.120 | ||||
| 2023-07-12 | 2023-07-10 | 4 | RINGO WILLIAM R | SNSE | Common Stock | D | 4.466 | 23.399 | ||||||
| 2023-07-12 | 2023-07-10 | 4 | RICKS THOMAS G | SNSE | Common Stock | D | 4.466 | 8.932 | ||||||
| 2023-07-12 | 2023-07-10 | 4 | Broder Samuel | SNSE | Common Stock | D | 4.466 | 8.932 | ||||||
| 2023-07-12 | 2023-07-10 | 4 | Humer Kristian | SNSE | Common Stock | D | 4.466 | 8.932 | ||||||
| 2023-07-12 | 2023-07-10 | 4 | English Jessie | SNSE | Common Stock | D | 4.466 | 8.932 | ||||||
| 2023-07-12 | 2023-07-10 | 4 | Holmen Bob | SNSE | Common Stock | D | 4.466 | 25.598 | ||||||
| 2023-07-12 | 2023-07-10 | 4 | Vojta Deneen | SNSE | Common Stock | D | 4.466 | 8.932 | ||||||
| 2023-07-12 | 2023-07-10 | 4 | Peyer James | SNSE | Common Stock | I | 4.466 | 5.240.422 | ||||||
| 2023-07-12 | 2023-07-10 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4.466 | 5.240.422 | ||||||
| 2023-06-02 | 2023-06-01 | 4 | Apeiron Investment Group Ltd. By Presight Sensei Co-Invest Fund, L.P. | SNSE | Common Stock | I | 1,5800 | -955.738 | -1.510 | 0 | ||||
| 2023-06-02 | 2023-06-01 | 4 | Apeiron Investment Group Ltd. By Apeiron Investment Group Ltd. | SNSE | Common Stock | I | 1,5800 | -2.485.923 | -3.928 | 0 | ||||
| 2023-03-29 | 2023-02-15 | 4/A | Gallagher Patrick Stephen | SNSE | Common Stock | D | 14.200 | 43.513 | ||||||
| 2023-03-29 | 2023-02-15 | 4/A | Gallagher Patrick Stephen | SNSE | Common Stock | D | 29.313 | 29.313 | ||||||
| 2023-03-29 | 2023-02-15 | 4/A | Celebi John | SNSE | Common Stock | D | 21.300 | 131.303 | ||||||
| 2023-03-29 | 2023-02-15 | 4/A | Celebi John | SNSE | Common Stock | D | 51.893 | 110.003 | ||||||
| 2023-03-29 | 2023-02-15 | 4/A | Colgan Erin | SNSE | Common Stock | D | 21.300 | 79.032 | ||||||
| 2023-03-29 | 2023-02-15 | 4/A | Colgan Erin | SNSE | Common Stock | D | 30.046 | 57.732 | ||||||
| 2023-03-07 | 2022-06-10 | 4/A | Cambrian BioPharma Inc | SNSE | Restricted Stock Unit Grant | D | 4.466 | 5.235.956 | ||||||
| 2023-02-27 | 2023-02-23 | 4 | Apeiron Investment Group Ltd. By Apeiron Investment Group Ltd. | SNSE | Common Stock | I | 1,6023 | 1.100 | 2 | 2.485.923 | ||||
| 2023-02-27 | 2023-02-23 | 4 | Apeiron Investment Group Ltd. By Apeiron Investment Group Ltd. | SNSE | Common Stock | I | 1,6150 | 1.100 | 2 | 2.484.823 | ||||
| 2023-02-17 | 2023-02-15 | 4 | Celebi John | SNSE | Common Stock | D | 21.300 | 127.307 | ||||||
| 2023-02-17 | 2023-02-15 | 4 | Celebi John | SNSE | Common Stock | D | 51.893 | 106.007 | ||||||
| 2023-02-17 | 2023-02-15 | 4 | Gallagher Patrick Stephen | SNSE | Common Stock | D | 14.200 | 43.515 | ||||||
| 2023-02-17 | 2023-02-15 | 4 | Gallagher Patrick Stephen | SNSE | Common Stock | D | 29.313 | 29.313 | ||||||
| 2023-02-17 | 2023-02-15 | 4 | Colgan Erin | SNSE | Common Stock | D | 21.300 | 73.032 | ||||||
| 2023-02-17 | 2023-02-15 | 4 | Colgan Erin | SNSE | Common Stock | D | 30.046 | 51.732 | ||||||
| 2023-02-17 | 2023-02-15 | 4 | van der Horst Edward | SNSE | Common Stock | D | 17.700 | 62.438 | ||||||
| 2023-02-17 | 2023-02-15 | 4 | van der Horst Edward | SNSE | Common Stock | D | 23.565 | 44.738 | ||||||
| 2022-12-16 | 3 | van der Horst Edward | SNSE | Common Stock | D | 21.173 | ||||||||
| 2022-08-01 | 2022-06-10 | 4/A | Peyer James | SNSE | Restricted Stock Unit Grant | I | 4.466 | 5.235.956 | ||||||
| 2022-08-01 | 3/A | Peyer James | SNSE | Common Stock | I | 2.282.827 | ||||||||
| 2022-07-20 | 3 | Presight Co-Invest Management, L.L.C. By Presight Sensei Co-Invest Fund, L.P. | SNSE | Common Stock | I | 955.738 | ||||||||
| 2022-07-20 | 3 | Presight Co-Invest Management, L.L.C. By Apeiron Investment Group Ltd. | SNSE | Common Stock | I | 2.483.723 | ||||||||
| 2022-06-14 | 2022-06-10 | 4 | Cambrian BioPharma Inc | SNSE | Restricted Stock Unit Grant | D | 4.466 | 5.235.954 | ||||||
| 2022-06-14 | 2022-06-10 | 4 | Peyer James | SNSE | Restricted Stock Unit Grant | I | 4.466 | 5.235.954 | ||||||
| 2022-06-14 | 2022-06-10 | 4 | Humer Kristian | SNSE | Common Stock | D | 4.466 | 4.466 | ||||||
| 2022-06-14 | 2022-06-10 | 4 | Vojta Deneen | SNSE | Common Stock | D | 4.466 | 4.466 | ||||||
| 2022-06-14 | 2022-06-10 | 4 | RICKS THOMAS G | SNSE | Common Stock | D | 4.466 | 4.466 | ||||||
| 2022-06-14 | 2022-06-10 | 4 | English Jessie | SNSE | Common Stock | D | 4.466 | 4.466 | ||||||
| 2022-06-14 | 2022-06-10 | 4 | Holmen Bob | SNSE | Common Stock | D | 4.466 | 21.132 | ||||||
| 2022-06-14 | 2022-06-10 | 4 | Broder Samuel | SNSE | Common Stock | D | 4.466 | 4.466 | ||||||
| 2022-06-10 | 2022-03-02 | 4/A | Cambrian BioPharma Inc | SNSE | Common Stock | D | 3,2000 | 1.203 | 4 | 5.231.488 | ||||
| 2022-06-10 | 2022-03-02 | 4/A | Peyer James | SNSE | Common Stock | I | 3,2000 | 1.203 | 4 | 5.231.488 | ||||
| 2022-04-21 | 2021-03-23 | 4/A | Peyer James | SNSE | Common Stock | I | 14,3400 | 9.500 | 136 | 4.798.293 | ||||
| 2022-04-21 | 2021-02-18 | 4/A | Peyer James | SNSE | Common Stock | I | 19,7500 | 752 | 15 | 4.690.905 | ||||
| 2022-04-21 | 2021-03-23 | 4/A | Cambrian BioPharma Inc | SNSE | Common Stock | D | 14,3400 | 9.500 | 136 | 4.798.293 | ||||
| 2022-04-21 | 2021-02-18 | 4/A | Cambrian BioPharma Inc | SNSE | Common Stock | D | 19,7500 | 752 | 15 | 4.690.905 | ||||
| 2022-03-09 | 2022-03-08 | 4 | RINGO WILLIAM R | SNSE | Stock Option (Right to Buy) | D | 3,08 | 29.100 | 29.100 | |||||
| 2022-03-09 | 2022-03-08 | 4 | RINGO WILLIAM R | SNSE | Common Stock | D | 10.000 | 18.933 | ||||||
| 2022-03-09 | 2022-03-08 | 4 | RINGO WILLIAM R | SNSE | Common Stock | D | 8.933 | 8.933 | ||||||
| 2022-03-02 | 2022-03-02 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 3,2000 | 1.203 | 4 | 5.231.989 | ||||
| 2022-03-02 | 2022-03-02 | 4 | Peyer James | SNSE | Common Stock | I | 3,2000 | 1.203 | 4 | 5.231.989 | ||||
| 2022-03-01 | 2022-03-01 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 3,6000 | 2.458 | 9 | 5.230.786 | ||||
| 2022-03-01 | 2022-02-28 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 3,6000 | 42 | 0 | 5.228.328 | ||||
| 2022-03-01 | 2022-03-01 | 4 | Peyer James | SNSE | Common Stock | I | 3,6000 | 2.458 | 9 | 5.230.786 | ||||
| 2022-03-01 | 2022-02-28 | 4 | Peyer James | SNSE | Common Stock | I | 3,6000 | 42 | 0 | 5.228.328 | ||||
| 2022-02-28 | 2022-02-25 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 3,6500 | 2.500 | 9 | 5.228.286 | ||||
| 2022-02-28 | 2022-02-25 | 4 | Peyer James | SNSE | Common Stock | I | 3,6500 | 2.500 | 9 | 5.228.286 | ||||
| 2022-02-24 | 2022-02-24 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 3,6300 | 15.000 | 54 | 5.225.786 | ||||
| 2022-02-24 | 2022-02-23 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 3,8000 | 2.500 | 10 | 5.210.786 | ||||
| 2022-02-24 | 2022-02-24 | 4 | Peyer James | SNSE | Common Stock | I | 3,6300 | 15.000 | 54 | 5.225.786 | ||||
| 2022-02-24 | 2022-02-23 | 4 | Peyer James | SNSE | Common Stock | I | 3,8000 | 2.500 | 10 | 5.210.786 | ||||
| 2022-02-22 | 2022-02-18 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 3,9700 | 15.000 | 60 | 5.208.286 | ||||
| 2022-02-22 | 2022-02-17 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4,1700 | 4.949 | 21 | 5.193.286 | ||||
| 2022-02-22 | 2022-02-18 | 4 | Peyer James | SNSE | Common Stock | I | 3,9700 | 15.000 | 60 | 5.208.286 | ||||
| 2022-02-22 | 2022-02-17 | 4 | Peyer James | SNSE | Common Stock | I | 4,1700 | 4.949 | 21 | 5.193.286 | ||||
| 2022-02-17 | 2022-02-15 | 4 | Pierce Robert Hamilton | SNSE | Stock Option (Right to Buy) | D | 4,30 | 62.000 | 62.000 | |||||
| 2022-02-17 | 2022-02-15 | 4 | Pierce Robert Hamilton | SNSE | Common Stock | D | 21.000 | 21.000 | ||||||
| 2022-02-17 | 2022-02-15 | 4 | Colgan Erin | SNSE | Stock Option (Right to Buy) | D | 4,30 | 62.000 | 62.000 | |||||
| 2022-02-17 | 2022-02-15 | 4 | Colgan Erin | SNSE | Common Stock | D | 21.000 | 21.686 | ||||||
| 2022-02-17 | 2022-02-15 | 4 | Celebi John | SNSE | Stock Option (Right to Buy) | D | 4,30 | 161.600 | 161.600 | |||||
| 2022-02-17 | 2022-02-15 | 4 | Celebi John | SNSE | Common Stock | D | 53.900 | 54.114 | ||||||
| 2022-02-16 | 2022-02-16 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4,2500 | 2.551 | 11 | 5.188.337 | ||||
| 2022-02-16 | 2022-02-14 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4,1800 | 10.000 | 42 | 5.185.786 | ||||
| 2022-02-16 | 2022-02-16 | 4 | Peyer James | SNSE | Common Stock | D | 4,2500 | 2.551 | 11 | 5.188.337 | ||||
| 2022-02-16 | 2022-02-14 | 4 | Peyer James | SNSE | Common Stock | I | 4,1800 | 10.000 | 42 | 5.185.786 | ||||
| 2022-02-14 | 2022-02-11 | 4 | Peyer James | SNSE | Common Stock | I | 4,4000 | 12.500 | 55 | 5.175.786 | ||||
| 2022-02-14 | 2022-02-10 | 4 | Peyer James | SNSE | Common Stock | I | 4,5800 | 5.000 | 23 | 5.163.286 | ||||
| 2022-02-14 | 2022-02-11 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4,4000 | 12.500 | 55 | 5.175.786 | ||||
| 2022-02-14 | 2022-02-10 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4,5800 | 5.000 | 23 | 5.163.286 | ||||
| 2022-02-08 | 2022-02-08 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4,3300 | 10.000 | 43 | 5.158.286 | ||||
| 2022-02-08 | 2022-02-04 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4,4500 | 2.500 | 11 | 5.148.286 | ||||
| 2022-02-08 | 2022-02-03 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4,6500 | 17.500 | 81 | 5.145.786 | ||||
| 2022-02-08 | 2022-02-08 | 4 | Peyer James | SNSE | Common Stock | I | 4,3300 | 10.000 | 43 | 5.158.286 | ||||
| 2022-02-08 | 2022-02-04 | 4 | Peyer James | SNSE | Common Stock | I | 4,4500 | 2.500 | 11 | 5.148.286 | ||||
| 2022-02-08 | 2022-02-03 | 4 | Peyer James | SNSE | Common Stock | I | 4,6500 | 17.500 | 81 | 5.145.786 | ||||
| 2022-01-31 | 2022-01-28 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4,2200 | 8.900 | 38 | 5.128.286 | ||||
| 2022-01-31 | 2022-01-27 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4,3100 | 6.100 | 26 | 5.119.386 | ||||
| 2022-01-31 | 2022-01-28 | 4 | Peyer James | SNSE | Common Stock | I | 4,2200 | 8.900 | 38 | 5.128.286 | ||||
| 2022-01-31 | 2022-01-27 | 4 | Peyer James | SNSE | Common Stock | I | 4,3100 | 6.100 | 26 | 5.119.386 | ||||
| 2022-01-27 | 2022-01-26 | 4 | Peyer James | SNSE | Common Stock | I | 4,6200 | 29.900 | 138 | 5.113.286 | ||||
| 2022-01-27 | 2022-01-25 | 4 | Peyer James | SNSE | Common Stock | I | 4,8600 | 20.100 | 98 | 5.083.386 | ||||
| 2022-01-27 | 2022-01-26 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4,6200 | 29.900 | 138 | 5.113.286 | ||||
| 2022-01-27 | 2022-01-25 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4,8600 | 20.100 | 98 | 5.083.386 | ||||
| 2022-01-25 | 2022-01-24 | 4 | Peyer James | SNSE | Common Stock | I | 4,6900 | 22.707 | 106 | 5.063.286 | ||||
| 2022-01-25 | 2022-01-21 | 4 | Peyer James | SNSE | Common Stock | I | 4,9400 | 24.703 | 122 | 5.040.579 | ||||
| 2022-01-25 | 2022-01-24 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4,6900 | 22.707 | 106 | 5.063.286 | ||||
| 2022-01-25 | 2022-01-21 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4,9400 | 24.703 | 122 | 5.040.579 | ||||
| 2022-01-21 | 2022-01-20 | 4 | Peyer James | SNSE | Common Stock | I | 5,1700 | 20.000 | 103 | 5.015.876 | ||||
| 2022-01-21 | 2022-01-19 | 4 | Peyer James | SNSE | Common Stock | I | 4,9700 | 10.244 | 51 | 4.995.876 | ||||
| 2022-01-21 | 2022-01-20 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 5,1700 | 20.000 | 103 | 5.015.876 | ||||
| 2022-01-21 | 2022-01-19 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4,9700 | 10.244 | 51 | 4.995.876 | ||||
| 2022-01-20 | 2022-01-18 | 4 | Peyer James | SNSE | Common Stock | I | 5,0800 | 10.000 | 51 | 4.985.632 | ||||
| 2022-01-20 | 2022-01-18 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 5,0800 | 10.000 | 51 | 4.985.632 | ||||
| 2022-01-18 | 2022-01-14 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4,9900 | 6.219 | 31 | 4.975.632 | ||||
| 2022-01-18 | 2022-01-13 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 5,1300 | 19.953 | 102 | 4.969.413 | ||||
| 2022-01-18 | 2022-01-14 | 4 | Peyer James | SNSE | Common Stock | I | 4,9900 | 6.219 | 31 | 4.975.632 | ||||
| 2022-01-18 | 2022-01-13 | 4 | Peyer James | SNSE | Common Stock | I | 5,1300 | 19.953 | 102 | 4.969.413 | ||||
| 2022-01-13 | 2022-01-12 | 4 | Peyer James | SNSE | Common Stock | I | 5,2200 | 9.202 | 48 | 4.949.460 | ||||
| 2022-01-13 | 2022-01-11 | 4 | Peyer James | SNSE | Common Stock | I | 5,1800 | 10.845 | 56 | 4.940.258 | ||||
| 2022-01-13 | 2022-01-12 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 5,2200 | 9.202 | 48 | 4.949.460 | ||||
| 2022-01-13 | 2022-01-11 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 5,1800 | 10.845 | 56 | 4.940.258 | ||||
| 2022-01-11 | 2022-01-10 | 4 | Peyer James | SNSE | Common Stock | I | 5,2800 | 10.000 | 53 | 4.929.413 | ||||
| 2022-01-11 | 2022-01-10 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 5,2800 | 10.000 | 53 | 4.929.413 | ||||
| 2022-01-03 | 2021-12-30 | 4 | Peyer James | SNSE | Common Stock | I | 4,8500 | 1.127 | 5 | 4.919.413 | ||||
| 2022-01-03 | 2021-12-30 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4,8500 | 1.127 | 5 | 4.919.413 | ||||
| 2021-12-30 | 2021-12-29 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 4,9800 | 69.000 | 344 | 4.918.286 | ||||
| 2021-12-30 | 2021-12-29 | 4 | Peyer James | SNSE | Common Stock | I | 4,9800 | 69.000 | 344 | 4.918.286 | ||||
| 2021-12-29 | 2021-12-28 | 4 | Peyer James | SNSE | Common Stock | I | 5,2800 | 11.288 | 60 | 4.849.286 | ||||
| 2021-12-29 | 2021-12-28 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 5,2800 | 11.288 | 60 | 4.849.286 | ||||
| 2021-12-27 | 2021-12-27 | 4 | Peyer James | SNSE | Common Stock | I | 5,3000 | 3.712 | 20 | 4.837.998 | ||||
| 2021-12-27 | 2021-12-27 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 5,3000 | 3.712 | 20 | 4.837.998 | ||||
| 2021-12-23 | 2021-12-23 | 4 | Peyer James | SNSE | Common Stock | I | 5,2700 | 11.000 | 58 | 4.834.286 | ||||
| 2021-12-23 | 2021-12-23 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 5,2700 | 11.000 | 58 | 4.834.286 | ||||
| 2021-12-21 | 2021-12-17 | 4 | Peyer James | SNSE | Common Stock | I | 5,2900 | 117 | 1 | 4.823.286 | ||||
| 2021-12-21 | 2021-12-17 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 5,2900 | 117 | 1 | 4.823.286 | ||||
| 2021-12-20 | 2021-12-16 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 5,2500 | 10.925 | 57 | 4.823.169 | ||||
| 2021-12-20 | 2021-12-16 | 4 | Peyer James | SNSE | Common Stock | I | 5,2500 | 10.925 | 57 | 4.823.169 | ||||
| 2021-12-13 | 2021-12-10 | 4 | RICKS THOMAS G | SNSE | Common Stock | I | 5,8600 | 20.000 | 117 | 341.769 | ||||
| 2021-12-13 | 2021-12-09 | 4 | RICKS THOMAS G | SNSE | Common Stock | I | 6,6200 | 20.000 | 132 | 321.769 | ||||
| 2021-08-12 | 2021-08-11 | 4 | Pierce Robert Hamilton By spouse | SNSE | Common Stock | I | 7,3436 | -16.030 | -118 | 0 | ||||
| 2021-08-10 | 2021-08-10 | 4 | Pierce Robert Hamilton By spouse | SNSE | Common Stock | I | 7,1289 | -66.350 | -473 | 16.030 | ||||
| 2021-08-10 | 2021-08-09 | 4 | Pierce Robert Hamilton By spouse | SNSE | Common Stock | I | 7,0603 | -6.982 | -49 | 82.380 | ||||
| 2021-08-10 | 2021-08-06 | 4 | Pierce Robert Hamilton By spouse | SNSE | Common Stock | I | 7,1127 | -6.460 | -46 | 89.362 | ||||
| 2021-08-10 | 3/A | Pierce Robert Hamilton By spouse | SNSE | Common Stock | I | 95.822 | ||||||||
| 2021-08-02 | 2021-07-30 | 4 | Humer Kristian | SNSE | Stock Option (Right to Buy) | D | 7,89 | 16.667 | 16.667 | |||||
| 2021-05-06 | 2021-05-05 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 12,0000 | 350 | 4 | 4.812.244 | ||||
| 2021-05-06 | 2021-05-05 | 4 | Peyer James | SNSE | Common Stock | I | 12,0000 | 350 | 4 | 4.812.244 | ||||
| 2021-04-21 | 2021-04-20 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 12,7700 | 385 | 5 | 4.811.894 | ||||
| 2021-04-21 | 2021-04-20 | 4 | Peyer James | SNSE | Common Stock | I | 12,7700 | 385 | 5 | 4.811.894 | ||||
| 2021-04-20 | 2021-04-19 | 4 | Peyer James | SNSE | Common Stock | I | 13,3800 | 1.965 | 26 | 4.811.509 | ||||
| 2021-04-20 | 2021-04-19 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 13,3800 | 1.965 | 26 | 4.811.509 | ||||
| 2021-04-14 | 2021-04-13 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 14,0000 | 2.000 | 28 | 4.809.544 | ||||
| 2021-04-14 | 2021-04-13 | 4 | Peyer James | SNSE | Common Stock | I | 14,0000 | 2.000 | 28 | 4.809.544 | ||||
| 2021-04-08 | 2021-04-07 | 4 | Peyer James | SNSE | Common Stock | I | 14,0000 | 2.000 | 28 | 4.807.544 | ||||
| 2021-04-08 | 2021-04-07 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 14,0000 | 2.000 | 28 | 4.807.544 | ||||
| 2021-04-05 | 2021-04-01 | 4 | English Jessie | SNSE | Stock Option (Right to Buy) | D | 14,42 | 16.667 | 16.667 | |||||
| 2021-04-02 | 2021-04-01 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 14,0000 | 1.000 | 14 | 4.805.544 | ||||
| 2021-04-02 | 2021-04-01 | 4 | Peyer James | SNSE | Common Stock | I | 14,0000 | 1.000 | 14 | 4.805.544 | ||||
| 2021-03-31 | 2021-03-30 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 12,0000 | 2.000 | 24 | 4.804.544 | ||||
| 2021-03-31 | 2021-03-30 | 4 | Peyer James | SNSE | Common Stock | I | 12,0000 | 2.000 | 24 | 4.804.544 | ||||
| 2021-03-25 | 2021-03-24 | 4 | Peyer James | SNSE | Common Stock | I | 14,1200 | 3.750 | 53 | 4.802.544 | ||||
| 2021-03-25 | 2021-03-24 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 14,1200 | 3.750 | 53 | 4.802.544 | ||||
| 2021-03-24 | 2021-03-23 | 4 | Peyer James | SNSE | Common Stock | I | 14,3400 | 10.000 | 143 | 4.798.794 | ||||
| 2021-03-24 | 2021-03-23 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 14,3400 | 10.000 | 143 | 4.798.794 | ||||
| 2021-03-23 | 2021-03-22 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 15,0200 | 2.183 | 33 | 4.788.794 | ||||
| 2021-03-23 | 2021-03-22 | 4 | Peyer James | SNSE | Common Stock | I | 15,0200 | 2.183 | 33 | 4.788.794 | ||||
| 2021-03-19 | 2021-03-18 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 15,2500 | 817 | 12 | 4.786.611 | ||||
| 2021-03-19 | 2021-03-18 | 4 | Peyer James | SNSE | Common Stock | I | 15,2500 | 817 | 12 | 4.786.611 | ||||
| 2021-03-10 | 2021-03-08 | 4 | Peyer James | SNSE | Common Stock | I | 15,2490 | 1.000 | 15 | 4.785.794 | ||||
| 2021-03-10 | 2021-03-08 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 15,2490 | 1.000 | 15 | 4.785.794 | ||||
| 2021-03-08 | 2021-03-05 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 13,7500 | 8.000 | 110 | 4.784.794 | ||||
| 2021-03-08 | 2021-03-05 | 4 | Peyer James | SNSE | Common Stock | I | 13,7500 | 8.000 | 110 | 4.784.794 | ||||
| 2021-03-05 | 2021-03-04 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 14,1250 | 2.000 | 28 | 4.776.794 | ||||
| 2021-03-05 | 2021-03-03 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 15,8500 | 3.000 | 48 | 4.774.794 | ||||
| 2021-03-05 | 2021-03-04 | 4 | Peyer James | SNSE | Common Stock | I | 14,1250 | 2.000 | 28 | 4.776.794 | ||||
| 2021-03-05 | 2021-03-03 | 4 | Peyer James | SNSE | Common Stock | I | 15,8500 | 3.000 | 48 | 4.774.794 | ||||
| 2021-03-03 | 2021-03-02 | 4 | Peyer James | SNSE | Common Stock | I | 16,2500 | 3.000 | 49 | 4.771.794 | ||||
| 2021-03-03 | 2021-03-02 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 16,2500 | 3.000 | 49 | 4.771.794 | ||||
| 2021-03-02 | 2021-02-26 | 4 | Peyer James | SNSE | Common Stock | I | 16,2500 | 5.000 | 81 | 4.768.794 | ||||
| 2021-03-02 | 2021-02-26 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 16,2500 | 5.000 | 81 | 4.768.794 | ||||
| 2021-02-26 | 2021-02-25 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 15,7900 | 12.000 | 189 | 4.763.794 | ||||
| 2021-02-26 | 2021-02-24 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 18,4200 | 900 | 17 | 4.751.794 | ||||
| 2021-02-26 | 2021-02-24 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 16,8400 | 18.100 | 305 | 4.750.894 | ||||
| 2021-02-26 | 2021-02-25 | 4 | Peyer James | SNSE | Common Stock | I | 15,7900 | 12.000 | 189 | 4.763.794 | ||||
| 2021-02-26 | 2021-02-24 | 4 | Peyer James | SNSE | Common Stock | I | 18,4200 | 900 | 17 | 4.751.794 | ||||
| 2021-02-26 | 2021-02-24 | 4 | Peyer James | SNSE | Common Stock | I | 16,8400 | 18.100 | 305 | 4.750.894 | ||||
| 2021-02-25 | 2021-02-23 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 18,1000 | 14.300 | 259 | 4.732.794 | ||||
| 2021-02-25 | 2021-02-23 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 17,0400 | 6.000 | 102 | 4.718.494 | ||||
| 2021-02-25 | 2021-02-23 | 4 | Peyer James | SNSE | Common Stock | I | 18,1000 | 14.300 | 259 | 4.732.794 | ||||
| 2021-02-25 | 2021-02-23 | 4 | Peyer James | SNSE | Common Stock | I | 17,0400 | 6.000 | 102 | 4.718.494 | ||||
| 2021-02-24 | 2021-02-22 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 18,8800 | 9.802 | 185 | 4.712.494 | ||||
| 2021-02-24 | 2021-02-22 | 4 | Peyer James | SNSE | Common Stock | I | 18,8800 | 9.802 | 185 | 4.712.494 | ||||
| 2021-02-23 | 2021-02-19 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 19,7700 | 11.786 | 233 | 4.702.692 | ||||
| 2021-02-23 | 2021-02-19 | 4 | Peyer James | SNSE | Common Stock | I | 19,7700 | 11.786 | 233 | 4.702.692 | ||||
| 2021-02-19 | 2021-02-18 | 4 | Peyer James | SNSE | Common Stock | I | 19,7500 | 753 | 15 | 4.690.906 | ||||
| 2021-02-19 | 2021-02-18 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 19,7500 | 753 | 15 | 4.690.906 | ||||
| 2021-02-10 | 2021-02-08 | 4 | RICKS THOMAS G | SNSE | Series BB Preferred Convertible Stock | I | -3.037.849 | 0 | ||||||
| 2021-02-10 | 2021-02-08 | 4 | RICKS THOMAS G | SNSE | Series AA Preferred Convertible Stock | I | -11.447.156 | 0 | ||||||
| 2021-02-10 | 2021-02-08 | 4 | RICKS THOMAS G | SNSE | Common Stock | I | 301.769 | 301.769 | ||||||
| 2021-02-10 | 2021-02-08 | 4 | Peyer James See footnotes | SNSE | Series BB Preferred Convertible Stock | I | -4.821.996 | 0 | ||||||
| 2021-02-10 | 2021-02-08 | 4 | Peyer James | SNSE | Series AA Preferred Convertible Stock | I | -110.729.827 | 0 | ||||||
| 2021-02-10 | 2021-02-08 | 4 | Peyer James | SNSE | Common Stock | I | 2.407.328 | 4.690.153 | ||||||
| 2021-02-10 | 2021-02-08 | 4 | H&S INVESTMENTS I LP | SNSE | Series AA Convertible Preferred Stock | D | -209.368.245 | 0 | ||||||
| 2021-02-10 | 2021-02-08 | 4 | H&S INVESTMENTS I LP | SNSE | Common Stock | D | 4.361.835 | 4.425.998 | ||||||
| 2021-02-10 | 2021-02-08 | 4 | Cambrian BioPharma Inc | SNSE | Series BB Preferred Convertible Stock | D | -4.821.996 | 0 | ||||||
| 2021-02-10 | 2021-02-08 | 4 | Cambrian BioPharma Inc | SNSE | Series AA Preferred Convertible Stock | D | -110.729.827 | 0 | ||||||
| 2021-02-10 | 2021-02-08 | 4 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 2.407.328 | 4.690.153 | ||||||
| 2021-02-05 | 2021-02-03 | 4 | Vojta Deneen | SNSE | Stock Option (Right to Buy) | D | 19,00 | 16.666 | 16.666 | |||||
| 2021-02-05 | 2021-02-03 | 4 | RICKS THOMAS G | SNSE | Stock Option (Right to Buy) | D | 19,00 | 16.666 | 16.666 | |||||
| 2021-02-05 | 2021-02-03 | 4 | Holmen Bob | SNSE | Stock Option (Right to Buy) | D | 19,00 | 16.666 | 16.666 | |||||
| 2021-02-05 | 2021-02-03 | 4 | Peyer James | SNSE | Stock Option (Right to Buy) | I | 19,00 | 16.666 | 16.666 | |||||
| 2021-02-05 | 2021-02-03 | 4 | Fjaellskog Marie-Louise | SNSE | Stock Option (Right to Buy) | D | 19,00 | 79.166 | 79.166 | |||||
| 2021-02-05 | 2021-02-03 | 4 | Hoey Anupama | SNSE | Stock Option (Right to Buy) | D | 19,00 | 83.333 | 83.333 | |||||
| 2021-02-05 | 2021-02-03 | 4 | Colgan Erin | SNSE | Stock Option (Right to Buy) | D | 19,00 | 52.083 | 52.083 | |||||
| 2021-02-05 | 2021-02-03 | 4 | Celebi John | SNSE | Stock Option (Right to Buy) | D | 19,00 | 416.666 | 416.666 | |||||
| 2021-02-05 | 2021-02-03 | 4 | Broder Samuel | SNSE | Stock Option (Right to Buy) | D | 19,00 | 16.666 | 16.666 | |||||
| 2021-02-05 | 2021-02-03 | 4 | Cambrian BioPharma Inc | SNSE | Stock Option (Right to Buy) | D | 19,00 | 16.666 | 16.666 | |||||
| 2021-02-03 | 3 | Pierce Robert Hamilton | SNSE | Common Stock | D | 73.463 | ||||||||
| 2021-02-03 | 3 | Holmen Bob | SNSE | Common Stock | D | 16.666 | ||||||||
| 2021-02-03 | 3 | Peyer James | SNSE | Common Stock | I | 2.282.825 | ||||||||
| 2021-02-03 | 3 | SAMUELI SUSAN | SNSE | Common Stock | D | 64.163 | ||||||||
| 2021-02-03 | 3 | Cambrian BioPharma Inc | SNSE | Common Stock | D | 2.282.825 |
